DESTINY-Breast11 delivers practice-changing data in the neoadjuvant setting. Can T-DXd replace anthracyclines for high-risk, HER2+ early-stage breast cancer? Drs. Pegram and Iyengar break down trial design, endpoints, and clinical impact.
DB11 and the Role of (T-DXd) in NACT high risk early stage HER2-Positive Breast Cancer
You may also like
Recommended Videos
